Hematological Parameters in Patients with Pulmonary Tuberculosis and its Presentation among Favorable and Unfavorable Treatment Outcomes

• Published in: Indian journal of public health 2024-07, Vol.68 (3), p.362-365
• Main Authors: Kumar, S Ramesh, Kandhasamy, Chandrasekaran, Velayutham, V Banurekha, Chinnaiyan, Ponnuraja, Kannan, Muthuramalingam, Jawahar, M S, Padmapriyadarsini, C
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Age Factors; Antitubercular Agents - therapeutic use; Blood; Blood Cell Count; clinical trial; Disease susceptibility; Female; Hematology; Hemoglobin; Hemoglobins - analysis; Humans; Information management; Leukocyte Count; Lymphocytes; Male; Medical research; Medicine, Experimental; Middle Aged; Moxifloxacin - administration & dosage; Moxifloxacin - therapeutic use; Neutrophils; outcome; Parameters; Patient outcomes; Platelets; Pulmonary tuberculosis; Sex Factors; Treatment Outcome; Tuberculosis; Tuberculosis, Pulmonary - blood; Tuberculosis, Pulmonary - drug therapy; white blood cell count; Young Adult
• ISSN: 0019-557X; 2229-7693
• DOI: 10.4103/ijph.ijph_918_23

Tuberculosis (TB) management continues to be a challenge globally; weakened immunity plays a significant role in the reactivation of TB. There is limited information on hematological parameters in patients with pulmonary TB and its association with outcome. We present hematological parameters of newly diagnosed sputum-positive pulmonary TB patients enrolled in a randomized, clinical trial that assessed the efficacy and safety of 3 and 4 regimens using moxifloxacin. Blood hematological parameters at baseline, comparison of the baseline and end of treatment values, including the monocytes by lymphocytes ratio (M/L), neutrophil lymphocyte ratio (N/L), and platelet lymphocyte ratio (P/L) between the patients with favorable and unfavorable TB treatment outcome, and among different age group and sex presented in this paper. Among the total 1059 patients, 782 were males, the mean hemoglobin (HB) ± standard deviation (SD) was 11.5 g/dL ± 2.0, the mean white blood cell (WBC) count ± SD was 9800 ± 3009 and the mean platelet count (in lakhs) ± SD was 4.24 ± 1.42 cells/uL. There was an increase from baseline in the mean hemoglobin, eosinophil, and lymphocyte count and a decrease in mean neutrophil, monocyte counts to the end of treatment. There was a decrease in baseline mean total WBC count posttreatment, both in favorable (10,271 cells/uL ± 3007 SD to 6689 cells/uL ± 1837 SD, [P ≤ 0.001]), and unfavorable TB outcome patients. An increase in HB, and a decrease in WBC count, M/L, N/L, and P/L ratio is possible at the end of TB treatment and future studies to correlate blood hematology parameters with TB treatment outcome.